Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
D000284:Administration, Oral; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000077613:Etoricoxib; D005260:Female; D006073:Gout / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006074:Gout Suppressants / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010147:Pain Measurement; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D006074:Gout Suppressants; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib; D007213:Indomethacin